DALLAS and FORT WORTH, Texas–( BUSINESS WIRE )–Feb. 1, 2023–
Satori Capital, a multi-strategy investment firm founded on the principles of conscious capitalism, today announced the launch of a new business focused on transformational companies developing innovative mental health solutions.
This press release contains multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005740/en/
Dr. Amy Kruse (Photo: Business Wire)
Satori Neuro targets companies developing breakthrough treatments and disruptive business models to address the world’s most critical mental health challenges. Supporting this kind of innovation aligns directly with Satori’s purpose: to create, fund and inspire businesses that uplift humanity.
“We have spent a significant amount of time and resources over the last several years evaluating opportunities related to mental health,” said James Haddaway, Chief Investment Officer and Managing Partner of Satori Alpha. “Because we believe so strongly in the enormous potential of these innovative solutions, we decided that if we could find the ideal Chief Investment Officer to lead a focused strategy, we would explore it ourselves.”
In searching for that ideal leader, Satori executives focused on the key qualities they believe are necessary for success in this cutting-edge sector. This Chief Investment Officer needs not only outstanding scientific and operational experience, but also deep connections with entrepreneurs and business leaders, and the ability to serve as a trusted and value-added partner to the strategy’s portfolio companies. Satori was also looking for a proven leader who would strongly align with Satori’s purpose and core values.
A widespread search led to such a leader: Dr. Amy Kruse. Dr. Kruse has more than 20 years of experience in science, technology and innovation, with a particular focus on neurotechnology and human performance. She is a former general partner at Prime Movers Lab, a venture capital firm that invests in early-stage science-driven startups developing solutions to some of the world’s most pressing problems. Previously, she served as Chief Science Officer of applied neuroscience research company Optios and has previous experience as Chief Technology Officer of Cubic Global Defense and as Program Manager at the Defense Advanced Research Projects Agency (DARPA). Dr. Kruse also holds a Bachelor of Science in Cell and Structural Biology and a Ph.D. in neuroscience from the University of Illinois Urbana-Champaign.
“Amy’s experience and subject matter expertise, as well as her impressive professional background, position her ideally to lead this innovative neuroscience and mental health strategy,” said Satori co-founder and managing partner Randy Eisenman. “Together with our executives’ operational experience in building and managing successful companies, we believe Amy’s unique expertise, experience and relationships give us a distinct advantage in identifying the most promising and innovative businesses in the sector.”
Satori’s assessment of Dr. Kruse’s preeminence in her field is borne out by the entrepreneurs and business leaders she has worked with in her previous roles, including Dr. Jonathan Spohrn, CEO of Gilgamesh Pharmaceuticals, a clinical-stage biotech company developing new drugs that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness.
“Amy is an ideal collaborator, both as an investor and thought partner,” said Spohrn. “She has played a key role in the success of our company, Gilgamesh Pharmaceuticals.” Amy is one of the most dynamic people I have worked with in my career, and she brings that energy to her venture work through every interaction. She is scientifically insightful, practical and incredibly relatable – any company would be lucky to have her on board.”
Under Dr. Kruse’s leadership, Satori Neuro will seek opportunities to address the greatest challenges and opportunities in mental health, brain health, and wellness. The innovative therapeutics included include a wide range of treatment approaches, from psychedelic medicine and transcranial magnetic stimulation to virtual/augmented reality protocols and non-invasive brainwave devices, all designed to provide solutions to challenges such as treatment-resistant depression, post-traumatic stress disorder, addiction and substance abuse, neurological disorders and more.
“This is an exciting time for neuroscience and brain health,” said Dr. Cruz. “We’ve learned more about the human brain in the last five years than we’ve previously learned in the last 50 – and that knowledge is rapidly being transformed into real-world applications that promise to completely transform our approach to the mental health challenges we face.” struggled with throughout human history. I think these innovations are the future of human flourishing, and I am delighted to partner with a purpose-driven firm like Satori in supporting companies developing breakthrough treatments and new business models.”
About Satori Capital
Satori Capital is a Texas-based multi-strategy investment firm founded on the principles of conscious capitalism. The firm’s purpose is to create, finance and inspire businesses that elevate humanity. Satori’s business partners in private equity through majority and minority investments with leadership teams of companies with EBITDA from $5 million to $50 million that operate with a long-term perspective, commit to their mission or purpose, and create value for all stakeholders. Satori’s alternative investment platform, Satori Alpha, creates and manages customized portfolios designed to meet the unique objectives of sophisticated private investors, family offices and institutions. Through its Satori XL partnership program, Satori partners with managers it believes are highly qualified to generate sustainable alpha and will benefit from Satori’s experience, relationships and resources, all in support of building thriving and resilient businesses. Satori Environmental invests in securities influenced by the global energy sector’s shift towards more renewable sources. For additional information, visit www.satoricapital.com.
View the original version on businesswire.com: https://www.businesswire.com/news/home/20230201005740/en/
CONTACT: Ellen Henderson
(214) 390-6270
KEYWORD: TEXAS United States NORTH AMERICA
INDUSTRY KEYWORD: PROFESSIONAL SERVICES MENTAL HEALTH HEALTH NEUROLOGY FINANCE GENERAL HEALTH
SOURCE: Satori Capital
Copyright Business Wire 2023.
PUB: 01.02.2023 13:23/DISC: 01.02.2023 13:22
http://www.businesswire.com/news/home/20230201005740/en
